Welcome to our dedicated page for Prenetics news (Ticker: PRE), a resource for investors and traders seeking the latest updates and insights on Prenetics stock.
Prenetics Global Ltd (PRE) delivers cutting-edge health solutions through genomics, clinical diagnostics, and blockchain-integrated platforms. This news hub provides investors and healthcare professionals with essential updates on the company developments shaping precision medicine and consumer wellness.
Access official press releases covering regulatory milestones, clinical trial results, and strategic partnerships. Stay informed about innovations across PRE's divisions including IM8 consumer health products, Insighta's cancer detection technologies, and CircleDNA's blockchain-enhanced testing services.
Our curated news collection features earnings reports, leadership updates, and scientific breakthroughs while maintaining strict compliance with financial disclosure standards. Bookmark this page for real-time updates on PRE's global initiatives in decentralized science and evidence-based healthcare solutions.
Prenetics (NASDAQ: PRE), a pioneering health sciences company, has announced a strategic partnership with international footballer and entrepreneur David Beckham. Beckham has invested in Prenetics and co-founded a new health and wellness brand, IM8, along with the company. IM8 will focus on innovative consumer health products, with further details forthcoming.
Beckham highlighted his lifelong access to top medical professionals and his excitement to work with Prenetics, a company dedicated to scientific advancements in health. Prenetics CEO Danny Yeung emphasized the transformative nature of this partnership, noting Beckham’s alignment with the company’s values of discipline, teamwork, and health.
Beckham's involvement includes collaboration with Prenetics shareholder Professor Dennis Lo, known for his pioneering work in non-invasive prenatal testing and early cancer detection. The partnership aims to drive significant contributions to the consumer health and wellness industry.
For more information, interested parties can join the waitlist at IM8health.com and follow IM8 Health on Instagram.
Prenetics Global (NASDAQ: PRE) has announced the addition of Kathryn M. Henry and David Vanderveen to its Board of Directors. This strategic move comes as Prenetics prepares to expand into the consumer health and wellness sector. CEO Danny Yeung believes that the extensive expertise of Henry and Vanderveen in consumer and health sectors will significantly enhance shareholder value. Henry brings experience from her roles at Lululemon and Gap, particularly in global information and technology operations. Vanderveen, with a robust 30-year track record in the beverage, nutrition, and technology sectors, is expected to contribute significantly to Prenetics' ambitious goals. Both directors expressed enthusiasm about their new roles and the company's potential for market disruption.
Prenetics Global (NASDAQ: PRE) has released its unaudited financial results for Q1 2024. The company reported a 30.2% increase in revenue to $6.4 million and a 159.8% rise in gross profit to $3.8 million compared to Q1 2023. Adjusted EBITDA improved by 55.9%, amounting to a loss of $4.1 million. Prenetics holds cash and short-term assets totaling $86.6 million. Insighta, a joint venture focused on early cancer detection, also had a cash balance of $79.8 million.
The company is strategically pivoting towards the U.S. consumer healthcare market, establishing dual headquarters in the U.S. and focusing on science-based health solutions. Insighta is progressing with promising pre-clinical data on prostate cancer and is set to commence a 1,500-person clinical trial in July 2024.
Prenetics Global (NASDAQ: PRE), a genomic-driven health sciences company, has partnered with MZ Group to lead a strategic investor relations and financial communications program. This collaboration aims to increase the company's visibility and communicate its technological advancements in health and wellness. Prenetics offers services like health-focused DNA tests, early cancer detection, and genomic profiling for targeted cancer therapy. With a strong cash position, no debt, and a dedicated management team, Prenetics is poised for growth and value creation for its shareholders. MZ Group, known for its expertise and global presence, will provide strategic counsel to Prenetics, enhancing market connections and communication strategies.
FAQ
What is the current stock price of Prenetics (PRE)?
What is the market cap of Prenetics (PRE)?
